CMS May Review Medicare Premium in Light of Aduhelm Price Drop

CMS May Review Medicare Premium in Light of Aduhelm Price Drop
Aduhelm, Biogen's approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providence, R.I., on June 16, 2021. Jessica Rinaldi/Pool via Reuters
Zachary Stieber
Updated:

President Joe Biden’s administration is considering a reassessment of Medicare Part B premiums after the drugmaker behind a new Alzheimer’s drug cut its price.

The administration announced in November 2021 that the monthly premium would rise by nearly $22 and attributed the rise in part to the potential use of Aduhelm, an Alzheimer’s drug from Biogen Inc.
Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth
Related Topics